CIK 882095
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Unclassified | 60.11% | 2 |
| Pharmaceuticals & Biotechnology | 39.89% | 4 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | ARCELLX INC | Unclassified | 36.44% | |
| 2 | RCUS | Arcus Biosciences, Inc. | Health Care | 32.05% |
| 3 | LKFT | GALAPAGOS NV | Unclassified | 23.67% |
| 4 | ASMB | ASSEMBLY BIOSCIENCES, INC. | Health Care | 5.90% |
| 5 | KYTX | Kyverna Therapeutics, Inc. | Health Care | 1.68% |
| 6 | XLO | Xilio Therapeutics, Inc. | Health Care | 0.26% |
4/6 names classified · sector 39.9% of weight · industry 39.9% · mkt cap 39.9%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 39.9% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/6 names) · unclassified 100.0%: , RCUS, LKFT, ASMB, KYTX, XLO. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | ARCELLX INC | 6,720,803 | $772M | 36.4% | HOLD |
| 2 | RCUSARCUS BIOSCIENCES INC | 31,424,760 | $679M | 32.1% | HOLD |
| 3 | LKFTGALAPAGOS NV | 16,707,477 | $501M | 23.7% | HOLD |
| 4 | ASMBASSEMBLY BIOSCIENCES INC | 4,505,391 | $125M | 5.9% | HOLD |
| 5 | KYTXKYVERNA THERAPEUTICS INC | 4,126,119 | $36M | 1.7% | HOLD |
| 6 | XLOXILIO THERAPEUTICS INC | 650,389 | $5M | 0.3% | TRIM −93% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| ARCELLX INC | 6.7M | 6.7M | 6.7M | 6.7M | 6.7M | 6.7M | $772M |
| RCUSARCUS BIOSCIENCES INC | 30.1M | 31.4M | 31.4M | 31.4M | 31.4M | 31.4M | $679M |
| LKFTGALAPAGOS NV | 16.7M | 16.7M | 16.7M | 16.7M | 16.7M | 16.7M | $501M |
| ASMBASSEMBLY BIOSCIENCES INC | 2.2M | 2.2M | 2.2M | 4.5M | 4.5M | 4.5M | $125M |
| KYTXKYVERNA THERAPEUTICS INC | 4.1M | 4.1M | 4.1M | 4.1M | 4.1M | 4.1M | $36M |
| XLOXILIO THERAPEUTICS INC | 9.1M | 9.1M | 9.1M | 9.1M | 9.1M | 650K | $5M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
